Jazz Pharmaceuticals director sells 6,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jazz Pharmaceuticals director Bruce C. Cozadd sold 6,000 Ordinary Shares on August 3, 2026 at $252.98 per share in a sale described as an open market or private transaction. The sale occurred automatically under a Rule 10b5-1 trading plan adopted on November 26, 2025, and does not represent a discretionary trade. Following this transaction, he directly holds 360,682 shares of Jazz Pharmaceuticals.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares F1 | 6,000 | $252.98 | $1.52M |
Footnotes (1)
- F1. This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Securities Exchange Act of 1934 regulatory
open market or private transaction market
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Jazz Pharmaceuticals (JAZZ) report?
What is Bruce Cozadd’s role at Jazz Pharmaceuticals (JAZZ) in this insider filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.